Skip to Main Content

Paper Details

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Investigational New Drugs
29
2018
B-cell, B-cell NHL, B-cell lymphoid malignancies, B-cell non-, CD37, CD37-binding antibody, DLBCL, DM1, Hodgkin lymphoma, IMGN529, NHL, diffuse large B-cell lymphoma, fatigue, febrile neutropenia, human, maytansinoid, neutropenia, non-Hodgkin lymphoma, patients, peripheral neuropathy, pyrexia, thrombocytopenia
Author NameAffiliation
Sumit MadanInstitute for Drug Development
  • 1 - 1

Datasets

Release 1.2